Skip to main content
. 2016 Mar 30;9(2):89–104. doi: 10.1111/cts.12391

Figure 1.

Figure 1

History of immunotherapy. Key events leading to the development of currently marketed immunotherapies including sipuleucel‐T (Provenge), ipilimumab (Yervoy), blinatumomab (BLINCYTO), nivolumab (Opdivo), pembrolizumab (Keytruda), and talimogene laherparepvec/T‐Vec (Imlygic).